WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2017066668) DRUG-LINKER CONJUGATE PHARMACEUTICAL COMPOSITIONS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2017/066668    International Application No.:    PCT/US2016/057177
Publication Date: 20.04.2017 International Filing Date: 14.10.2016
IPC:
C07C 49/788 (2006.01), C07C 49/792 (2006.01)
Applicants: BAYLOR UNIVERSITY [US/US]; 213 Pat Neff Hall, One Bear Place #97034 Waco, TX 76798 (US)
Inventors: PINNEY, Kevin, G.; (US).
LIN, Chen-ming; (US).
MONDAL, Deboprosad; (US).
FORD, Jacob; (US)
Agent: BUCKINGHAM, David, K.; (US).
SHAY, James, R.; (US).
GLENN, W., Benjamin; (US).
ZLOGAR, Thomas, M.; (US).
LIMBACH, Douglas, C.; (US)
Priority Data:
62/242,220 15.10.2015 US
Title (EN) DRUG-LINKER CONJUGATE PHARMACEUTICAL COMPOSITIONS
(FR) COMPOSITIONS PHARMACEUTIQUES DE CONJUGUÉ MÉDICAMENT-LIEUR
Abstract: front page image
(EN)Compositions are disclosed having a cytotoxic and/or vascular disrupting agent (VDA) payload attached to a linker. The linker can be a cathepsin B protease cleavable linker or a non-cleavable linker that may degrade intracellularly. Methods for making and using the compositions are also provided. The compositions can be provided to a patient in need thereof with the composition coming into contact with a cancer cell to activate or release the cytotoxic and/or vascular disrupting agent payload.
(FR)L'invention concerne des compositions comprenant une charge d'agent cytotoxique et/ou de perturbation vasculaire attachée à un lieur. Le lieur peut être un lieur clivable par la protéase cathepsine B ou un lieur non clivable qui peut se dégrader au niveau intracellulaire. L'invention concerne également des procédés de production et d'utilisation des compositions. Les compositions peuvent être administrées à un patient le nécessitant, la composition entrant en contact avec une cellule cancéreuse pour activer ou libérer la charge d'agent cytotoxique et/ou de perturbation vasculaire.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)